1.Triterpenes from Kalimeris indica.
Xiaojian GONG ; Xin ZHOU ; Chao ZHAO ; Huaguo CHEN ; Wenqing XU ; Shangxiang LONG
China Journal of Chinese Materia Medica 2010;35(3):327-330
OBJECTIVETo study the constituents of Kalimeris indica.
METHODThe constituents were isolated by various chromatographic techniques and their structures were elucidated by their physicochemical properties and the spectral data analysis.
RESULTEleven compounds were isolated and identified as dammaradienyl acetate(1), friedelin(2), friedelinol(3), beta-amyrin(4), alpha-amyrin(5), lupenyl acetate(6), beta-sitosterol(7), alpha-spinasterol(8), alpha-spinasterone(9), stigmasterol(10), daucosterol(11).
CONCLUSIONCompounds 4-6, 8-11 were isolated from the genus Kalimeris for the first time.
Asteraceae ; chemistry ; Magnetic Resonance Spectroscopy ; Plants, Medicinal ; chemistry ; Triterpenes ; chemistry
2.Laparoscopy and endoscopy cooperative surgery in the treatment of stomach neoplasms
Fanghai HAN ; Shangxiang CHEN ; Shengning ZHOU
Chinese Journal of Gastrointestinal Surgery 2023;26(8):745-752
With the rapid development of medical technology and the improvement of people's health awareness, the detection rate of benign gastric tumors and early gastric cancer has increased significantly. Under the premise of ensuring the safety of oncology, challenges for surgeons present is how to adopt precise and reasonable treatment plans according to the characteristics of gastric tumors to minimize surgical trauma and complications, improve postoperative quality of life, and achieve individualized and precise treatment. Laparoscopic surgery and digestive endoscopy are currently the two main methods for treating gastric tumors. However, they both have advantages and shortcomings. The combination of laparoscopy and digestive endoscopy for the treatment of gastric tumors has become a new way to treat gastric tumors. This operation not only fully exploits the advantages of laparoscopy and digestive endoscopy, but also complements the shortcomings of each. This article reviews the surgical technique categories, indications, technical improvements, and perspectives of laparoscopy combined with digestive endoscopy in the treatment of gastric tumors.
3.Laparoscopy and endoscopy cooperative surgery in the treatment of stomach neoplasms
Fanghai HAN ; Shangxiang CHEN ; Shengning ZHOU
Chinese Journal of Gastrointestinal Surgery 2023;26(8):745-752
With the rapid development of medical technology and the improvement of people's health awareness, the detection rate of benign gastric tumors and early gastric cancer has increased significantly. Under the premise of ensuring the safety of oncology, challenges for surgeons present is how to adopt precise and reasonable treatment plans according to the characteristics of gastric tumors to minimize surgical trauma and complications, improve postoperative quality of life, and achieve individualized and precise treatment. Laparoscopic surgery and digestive endoscopy are currently the two main methods for treating gastric tumors. However, they both have advantages and shortcomings. The combination of laparoscopy and digestive endoscopy for the treatment of gastric tumors has become a new way to treat gastric tumors. This operation not only fully exploits the advantages of laparoscopy and digestive endoscopy, but also complements the shortcomings of each. This article reviews the surgical technique categories, indications, technical improvements, and perspectives of laparoscopy combined with digestive endoscopy in the treatment of gastric tumors.
4.Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
Gao YUAN ; Li SU ; Xu DAZHI ; Chen SHANGXIANG ; Cai YUCHEN ; Jiang WENQI ; Zhang XINKE ; Sun JIN ; Wang KEFENG ; Chang BOYANG ; Wang FENGHUA ; Hong MINGHUANG
Chinese Journal of Cancer 2017;36(11):560-573
Background: Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials. However, the value of PD-L1 in predicting responses of patients with gastric cancer to anti-PD-1/PD-L1 immunotherapy is controversial. Some studies suggested that intra- and inter-tumoral heterogeneity of PD-L1 expression might explain the controversy. This study aimed to analyze the expression of PD-L1, PD-L2, and PD-1 as well as CD8(+) T-cell density in primary tumors and lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma to explore the heterogeneity of PD-1 signaling pathway molecules. Methods: In primary tumors and metastatic as well as non-metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma, we detected PD-L1 and PD-L2 expression with immunohistochemistry. CD8(+) T-cell density in primary tumors and PD-1 expression on CD8(+) T cells were detected with immunofluorescence. Uni-variate analysis was used to determine the prognostic values of them. Cox proportional hazard regression model was used to identify independent risk factors that affect patients' overall survival and disease-free survival. Results: Among 119 eligible patients who had undergone surgical resection, the positive rate of PD-L1 was higher in metastatic lymph nodes than in primary tumors (45.4% vs. 38.7%,P= 0.005); the positive rate of PD-1 on CD8(+) T cells was significantly higher in primary tumors and metastatic lymph nodes than in tumor-free lymph nodes (both P < 0.001). The intensity of PD-1 expression on CD8(+) T cells in primary tumors and in metastatic lymph nodes were stronger than that in tumor-free lymph nodes from the same patient. Beside, the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis.Conclusion: The expression of PD-L1 is heterogeneous in primary tumors and in metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma, which might explain the inconsistent results in assessing the prognostic value of PD-L1 expression in previous studies.